% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hoppe:274576,
      author       = {B. S. Hoppe and I. A. Petersen and B. K. Wilke and T. A.
                      DeWees and R. Imai and E. B. Hug and M. R. Fiore and J.
                      Debus$^*$ and P. Fossati and S. Yamada and E. Orlandi and Q.
                      Zhang and C. Bao and K. Seidensaal$^*$ and B. C. May and A.
                      C. Harrell and M. T. Houdek and L. A. Vallow and P. S. Rose
                      and M. G. Haddock and J. B. Ashman and K. A. Goulding and S.
                      Attia and S. Krishnan and A. Mahajan and R. L. Foote and N.
                      N. Laack and S. R. Keole and C. J. Beltran and E. M. Welch
                      and M. Karim and S. K. Ahmed},
      title        = {{P}ragmatic, {P}rospective {C}omparative {E}ffectiveness
                      {T}rial of {C}arbon {I}on {T}herapy, {S}urgery, and {P}roton
                      {T}herapy for the {M}anagement of {P}elvic {S}arcomas
                      ({S}oft {T}issue/{B}one) {I}nvolving the {B}one: {T}he
                      {PROSPER} {S}tudy {R}ationale and {D}esign.},
      journal      = {Cancers},
      volume       = {15},
      number       = {6},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-00653},
      pages        = {1660},
      year         = {2023},
      abstract     = {Surgical treatment of pelvic sarcoma involving the bone is
                      the standard of care but is associated with several sequelae
                      and reduced functional quality of life (QOL). Treatment with
                      photon and proton radiotherapy is associated with relapse.
                      Carbon ion radiotherapy (CIRT) may reduce both relapse rates
                      and treatment sequelae. The PROSPER study is a
                      tricontinental, nonrandomized, prospective, three-arm,
                      pragmatic trial evaluating treatments of pelvic sarcoma
                      involving the bone. Patients aged at least 15 years are
                      eligible for inclusion. Participants must have an Eastern
                      Cooperative Oncology Group Performance Status score of two
                      or less, newly diagnosed disease, and histopathologic
                      confirmation of pelvic chordoma, chondrosarcoma,
                      osteosarcoma, Ewing sarcoma with bone involvement,
                      rhabdomyosarcoma (RMS) with bone involvement, or non-RMS
                      soft tissue sarcoma with bone involvement. Treatment arms
                      include (1) CIRT (n = 30) delivered in Europe and Asia, (2)
                      surgical treatment with or without adjuvant radiotherapy (n
                      = 30), and (3) proton therapy (n = 30). Arms two and three
                      will be conducted at Mayo Clinic campuses in Arizona,
                      Florida, and Minnesota. The primary end point is to compare
                      the 1-year change in functional QOL between CIRT and
                      surgical treatment. Additional comparisons among the three
                      arms will be made between treatment sequelae, local control,
                      and other QOL measures.},
      keywords     = {cancer treatment (Other) / carbon ion (Other) / clinical
                      trial (Other) / pelvic sarcoma (Other) / proton therapy
                      (Other) / radiotherapy (Other) / surgical treatment (Other)},
      cin          = {E050},
      ddc          = {610},
      cid          = {I:(DE-He78)E050-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36980545},
      pmc          = {pmc:PMC10046156},
      doi          = {10.3390/cancers15061660},
      url          = {https://inrepo02.dkfz.de/record/274576},
}